BRCA

This time last year, pre-pandemic, 23andMe brought together a panel of inspiring women to raise awareness about breast cancer.The message was clear. Knowledge — about risks, treatments, and the resources...

A new 23andMe study found that many with a BRCA genetic variant associated with an increased risk for breast, ovarian, and other cancers do not have a strong family history of cancer meaning they would likely not qualify for clinical genetic testing under current criteria.

Using 23andMe Jessica learned she carries a BRCA1 variant that puts her at risk for breast or ovarian cancer a risk she wouldn't have learned of otherwise. Like many other women with a similar risk, she slipped through the cracks for traditional screening because she didn't meet the current criteria.

For Breast Cancer Awareness Month, we wanted to shed some light on something you might not know. Studies suggest that more than half of individuals with a cancer-related variant in...

It’s February, which means the largest family discovery conference of the year is almost upon us. This year, 23andMe will be returning to Salt Lake City, Utah for RootsTech 2019....

Before we kick off the New Year, let’s look back and highlight a few important moments for us here at 23andMe in 2018.The Power of Big DataFor some types of...

23andMe makes the right gift for almost anyone during the holidays offering unique insights and personal discoveries for those who want to explore their DNA.

October is Breast Cancer Awareness Month, a time to draw attention and support for the importance of early detection and treatment of this disease. As part of Breast Cancer Awareness...

23andMe's new BRCA1/BRCA2 (Selected Variants) report looks at three variants in the BRCA1 and BRCA2 genes associated with an increased risk of breast, ovarian and prostate cancer. These three variants are most common in people of Ashkenazi Jewish descent, but having one of these variants carries serious risk no matter your ancestry.

23andMe received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk for its BRCA1/BRCA2 report. The report covers three variants in the BRCA1 and BRCA2 genes associated with increased risk for breast, ovarian, and prostate cancer.